Company Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.
It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder.
The company was founded in 2003 and is based in La Jolla, California.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | D. Kirkpatrick |
Contact Details
Address: 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 United States | |
| Phone | 858 263 4196 |
| Website | ensysce.com |
Stock Details
| Ticker Symbol | ENSC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001716947 |
| CUSIP Number | 293602108 |
| ISIN Number | US2936024056 |
| Employer ID | 82-2755287 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. D. Lynn Kirkpatrick Ph.D. | President, Chief Executive Officer and Director |
| Geoffrey Birkett | Chief Commercial Officer |
| Dr. Jeffrey Millard Ph.d. | Chief Operating Officer |
| Dr. William K. Schmidt Ph.D. | Chairman of Clinical Advisory Board and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | 8-K | Current Report |
| Oct 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 18, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 18, 2024 | ARS | Filing |
| Oct 17, 2024 | EFFECT | Notice of Effectiveness |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 10, 2024 | DEL AM | Filing |
| Oct 9, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 9, 2024 | POS AM | Post-Effective amendments for registration statement |